The orally active, α-hemoglobin derived hemopressin (PVNFKFLSH,) and its truncated (PVNFKFL, Hp(1-7) and PVNFKF, Hp(1-6)) and extended ((R)VDPVNFKFLSH, VD-Hp(1-9) and RVD-Hp(1-9)) derivatives have been postulated to be the endogenous peptide ligands of the cannabinoid receptor type 1 (CB1). In an attempt to create a versatile peptidic research tool for the direct study of the CB1 receptor-peptide ligand interactions, Hp(1-7) was radiolabeled and in vitro characterized in rat and CB1 knockout mouse brain membrane homogenates. In saturation and competition radioligand binding studies, [
Introduction
The endogenous, phyto-and synthetic cannabinoids exert their pharmacological effects through the activation of cannabinoid receptors. To date, the cannabinoid type 1 (CB1) and cannabinoid type 2 (CB2) receptors have been cloned that belong to the superfamily of G i /G o G-protein coupled receptors (Begg et al., 2005; Pertwee, 1997) . The CB1 receptors are primarily expressed in regions of the central nervous system (Herkenham et al., 1990; Matsuda et al., 1990) while CB2 receptors proved to be localized mainly in immune cells of the periphery (Munro et al., 1993) , though recent studies reported the presence of CB2 receptors in the brain stem and spinal cord as well (Van Sickle et al., 2005; Zhang et al., 2003) .
Lipid endocannabinoids are the best characterized endogenous ligands of the cannabinoid receptors and their physiological effects are primarily mediated through the CB1 receptors (Di Marzo and Petrosino, 2007; Boyd, 2006) . The activation of the CB1 receptor is thought to be responsible for the mediation of antinociception, hypothermia, hypotension, sedation and inhibition of locomotor activity (Manzanares et al., 1999 , Massi et al., 2001 . Consequently, drugs acting on the CB1 receptor and on the entire endocannabinoid system may have therapeutic potential in a number of pathological conditions such as obesity, metabolic syndromes, mood and anxiety disorders, neuropathic pain, inflammation, multiple sclerosis, spinal cord injuries, myocardial infarction, stroke, hypertension, cancer and osteoporosis (Pacher et al., 2006) .
Over the past decades, the lipid derived endocannabinoids were believed to be the sole endogenous agonists of the cannabinoid receptors. However, as a result of the pioneering works of Heimann et al. (2007) and Rioli et al. (2003) , hemopressin (PVNFKFLSH, Hp(1-9)) was identified as a putative inverse agonist peptide ligand of the CB1 receptor. This peptide is a metabolic product of the hemoglobin α-chain and it was demonstrated to exert non-opioid antinociceptive effects, similar to those of the endo-, phyto-and synthetic cannabinoids (Heimann et al., 2007; Hama and Sagen, 2011) . In an in vivo model of arthritic pain Hp(1-9) failed to mitigate mechanical allodynia (Petrovszki et al., 2012) , however, in other studies, it could prevent carrageen-and bradykinin-induced hyperalgesia (Dale et al., 2005) and chronic constriction injury-induced mechanical hyperalgesia, a model of neuropathic pain (Toniolo et al., 2014a (Toniolo et al., , 2014b . Hp(1-9) was also reported to induce weak, but dose-dependent hypotensive effects and to reduce food intake in rodents via a CB1 receptor-dependent manner (Blais et al., 2005; Rioli et al., 2003; Dodd et al., 2010 Dodd et al., , 2013 . Very recently, Hp(1-9) was suggested promoting oligodendrocytic differentiation and maturation of subventricular zone progenitor cells, of which processes have significance in myelination abnormalities (Xapelli et al., 2014) .
Soon after the discovery and pharmacological characterization of Hp(1-9), the RVD-and VD-extended RVD-Hp(1-9) and VD-Hp(1-9) (Gomes et al., 2009) , and the C-terminally truncated Hp(1-6) and Hp(1-7) peptides were identified as potent cannabinoid ligands (Dale et al., 2005) . RVD-Hp(1-9) and VD-Hp(1-9) were suggested being agonist ligands of the CB1 receptor. In vivo data for the C-terminally truncated hemopressins demonstrated that Hp(1-9) was not essential for antinociceptive activity, because Hp(1-6) and Hp(1-7) exerted as effective antihyperalgesic effects as the N-terminally extended peptides. Further C-terminal truncation, however, led to the loss of biological activity (Bomar and Galande, 2012) . VD-and RVD-Hps exhibited hypotensive, hypothermic and hypoactive effects at antinociceptive doses, and inhibited bombesin-induced central activation of the adrenomedullary outflow in rats (Tanaka et al., 2014; Han et al., 2014) . In addition, central administration of VD-Hp resulted in tolerance to antinociception and stimulated food consumption in a CB1-dependent manner Pan et al., 2014) . The signaling characteristics and regulation of receptor endocytosis of the N-terminally extended peptide fragments were found to be distinct, in part, from those of the classical cannabinoid agonists (Gomes et al., 2009) .
Circular dichroism, NMR spectroscopy and molecular docking studies on the Hp(1-9) and Hp(1-6) peptides showed that regular turn structures in the central portion of the peptides were essential for an interaction with the receptor, and similarly to the inverse agonist rimonabant the peptides stabilized receptor structures via H-bonds (Scrima et al., 2010) . This interaction was assumed to be important for the stabilization of the inactive state of CB1 receptor and provides structural basis for the explanation of the activity of hemopressin peptides as agonist.
These observations suggest that hemopressins are novel endogenous peptide ligands of the CB1 receptor, and may have potential for the development of peptide-based research tools or therapeutic agents for the study of the endocannabinoid system or the treatment of cannabinoid-related diseases. In the present study, we report on the synthesis and radiolabeling of the C-terminally truncated hemopressin peptide Hp(1-7) and the direct in vitro pharmacological characterization of the novel radioligand [ 3 H]Hp(1-7) in brain membrane homogenates of rat and CB1 knockout mouse. Our results suggest that the hemoglobin fragment Hp(1-7) may be a regulator of the endocannabinoid system and that [ 3 H]Hp(1-7) can label either a CB receptor binding site different from the classical cannabinoid ligand binding site or another membrane protein.
Materials and methods
The peptides Hp(1-7) (H-Pro-Val-Asn-Phe-Lys-Phe-Leu-OH), ΔPro 1 -Hp(1-7) (H-ΔPro-Val-Asn-Phe-Lys-Phe-Leu-OH), Hp(1-9) (HPro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-OH) and RVD-Hp(1-9) (H-ArgVal-Asp-Pro-Val-Asn-Phe-Lys-Leu-Leu-Ser-His-OH) were synthesized and purified in our laboratory. The peptide synthesis resins, protected amino acids and the coupling reagent TBTU were purchased from Bachem. Hydrogen fluoride used for the cleavage of the peptides was obtained from PRAXAIR N.V. (Oevel, Belgium were added for chain elongation in DMF and the unreacted resinbound peptides were end-capped with an excess of Ac 2 O in the presence of DIEA in DMF. Couplings were monitored with the Kaiser-test (Kaiser et al., 1970) . After removal of the N-terminal protecting group, peptides were cleaved from the resin with HF in the presence of anisole. The crude peptide -resin mixtures were washed with diethylether, then the peptides were dissolved in aqueous TFA and lyophilized. The resulting crude peptides were dissolved in aqueous TFA, and introduced onto an analytical Vydac 218TP54 column and eluted using a linear gradient of 1.5% per min of acetonitrile in water containing 0.1% TFA, starting from 15% acetonitrile at a flow rate of 1 mL/min, λ = 215 nm. The same elution conditions were used for the purification of the peptides on a semipreparative Vydac 218TP1010 column at a flow rate of 4 mL/min; isolated yields 56% (Hp(1-7)), 74% (ΔPro 1 -Hp(1-7)), 38%
(Hp(1-9)) and 42% (RVD-Hp(1-9)). The precursor peptide ΔPro 1 -Hp(1-7) (2 mg, 2.32 μmol) was dissolved in DMF and 3 mg Pd/BaSO 4 catalyst was added to the solution. The reaction mixture was degassed prior to tritium reduction by a freeze-thaw cycle. Then it was stirred under 0.4 bar of tritium gas for 1 h at ambient temperature, followed by the filtration of the catalyst through a Whatman GF/C glass fiber filter. (1-7) were performed by RP-HPLC via UV and radioactivity detection using a calibration curve made by Hp(1-7), and the specific activity of [ 3 H]Hp(1-7) was found to be 1.04 TBq/mmol (28 Ci/mmol). The radioligand was aliquoted as ethanolic solutions and stored in liquid nitrogen until application.
Preparation of brain membrane homogenates
Wistar rats (male, 180-220 g) were housed locally ad libitum and handled according to the European Communities Council Directives (86/609/ECC) and to the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. Section 32). Crude membrane fractions were prepared from the brain without cerebellum. Brains were quickly removed from the euthanized rats and directly put in ice-cold 50 mM Tris/HCl (pH 7.4) buffer. The collected tissue was then homogenized in 30 volumes (v/w) of ice-cold buffer with a Teflon-glass Braun homogenizer at the highest rpm. The homogenate was centrifuged at 20,000g for 25 min. The supernatant was discarded and the resulting pellet was resuspended in 5 volumes (v/w) of ice-cold 50 mM Tris/ HCl (pH 7.4) buffer containing 0.32 M sucrose and stored in aliquots in liquid nitrogen. Prior to the experiment, aliquots were thawed and centrifuged at 20,000g for 25 min and the pellets were resuspended in 50 mM Tris/HCl (pH 7.4) containing 1% (w/v) BSA, homogenized with a Dounce followed by the determination of the protein content by the method of Bradford (Bradford, 1976 and were processed as described above. The CB1 knockout mouse strain was generated as described by Ledent and co-workers (Ledent et al., 1999) .
Receptor binding assays
All binding experiments were carried out at 37°C in plastic tubes in a final volume of 1 mL 50 mM Tris/HCl, 3 mM MgCl 2 working buffer (pH: 7.4) that contained 0.2-0.5 mg/mL membrane protein and 1% (w/v) BSA to reduce non-specific binding. Incubation mixtures were filtered through Whatman GF/B glass fiber filters with a Brandel Cell Harvester (serial#: 2620) and filters were pre-soaked and washed three times with 50 mM Tris/HCl (pH 7.4) washing buffer that contained 0.1% (w/v) BSA. Association kinetic curves were established by coincubating 2 nM [ 3 H]Hp(1-7) with the membrane preparation in the absence (total binding) or presence (non-specific binding) of 10 μM Hp(1-7). Dissociation kinetic curves were determined after preincubation of the membrane homogenate with 2 nM radioligand for 30 min in the presence of 1 mM EGTA, 1 mM EDTA, 2 mM PMSF and 0.1 mM bestatin to reach equilibrium, and then dissociation was initiated by the addition of 10 μM Hp(1-7) after the indicated periods of time. 30 min at 37°C. Non-specific binding was determined by the addition of 10 μM Hp(1-7). The samples were incubated in a shaking water bath and reactions were stopped by the addition of ice-cold washing buffer followed by fast filtration. The filters were immersed into an Ultima Gold XR scintillation cocktail and radioactivity was measured with a Packard Tri-Carb 2100 TR liquid scintillation analyzer. S]GTPγ S binding was measured in the absence of ligands and was set as 100%. Nonspecific binding was determined by the addition of 10 μM unlabeled GTPγS and subtracted from total binding. Incubation, filtration and radioactivity measurement were carried out as described above.
Data analysis
Results of the kinetic experiments are reported as means ± S.E.M. of at least three independent experiments each performed in duplicate.
Non-linear regression analyses of the association and dissociation curves and the direct saturation isotherms were performed to obtain the observed association rate constant (k obs ), the dissociation rate constant (k d ), the equilibrium dissociation constant (K d ) and the receptor density (B max ). In competition binding studies, the inhibitory constants (K i ) were calculated from the inflection points of the displacement curves using non-linear least-square curve fitting and the ChengPrusoff equation. All data and curves were analyzed by GraphPad Prism 4.0 (San Diego, CA, USA state in 5 min (Fig. 1A. ) that remained stable up to 60 min. The specific binding was 50-60% of the total binding at 2 nM radioligand concentration under equilibrium conditions. . It was found that 55% of the radioligand dissociated from the membranes. The kinetically derived equilibrium dissociation constant (K d ) calculated from the association and dissociation experiments was assessed to be 7.2 ± 1.2 nM under our experimental conditions.
Saturation
Saturation radioligand binding experiments were carried out in brain homogenates of rat and CB1 knockout mouse in the presence of increasing radioligand concentrations for 30 min. The specific binding of [ 3 H]Hp(1-7) was found to be saturable and of high affinity (nanomolar range) in both tissue homogenates ( Fig. 2A. and B. ). Single-site bindings were calculated for both saturation curves by non-linear fitting of the specific binding data points that resulted in dissociation equilibrium constants (K d ) of 14.5 ± 3.2 nM and 10.8 ± 1.8 nM in rat and in CB1 knockout mouse brain membrane, respectively. Furthermore, high receptor densities (B max = 830 ± 120 and 990 ± 145 fmol/mg protein in rat and in CB1 knockout mouse brain membranes, respectively) were observed ( (Fig. 3) . It was found that neither the non-selective cannabinoid full agonist JWH-018, the CB1 receptor inverse agonist AM251 nor the CB1 receptor inverse agonist rimonabant could displace the bound radioligand in rat brain membranes. Only the unlabeled Hp(1-7) was able to compete with its tritium labeled analog, with an apparently high inhibitory constant of 103 ± 23 nM. In contrast, a K d value of 14.5 ± 3.2 was obtained by the analysis of the kinetic curves. Next, competition binding experiments were performed to investigate the ability of hemopressins Hp(1-7), Hp(1-9) and RVD-Hp(1-9) to inhibit the binding of [ 3 H]Hp(1-7) in rat brain membrane homogenate (Fig. 4A.) .
These hemopressins could displace [ 3 H]Hp(1-7) from the binding site with different inhibitory constants ( Table 3) . The parent Hp(1-7) displayed the highest affinity (K i = 111 ± 14 nM) to the binding site. The Hp(1-9) peptide provided a slightly higher inhibitory constant (K i = 184 ± 28 nM) but still within the same order of magnitude. These data indicated that Hp(1-7) and Hp(1-9) might bind to the same site or conformation of a receptor protein, however both Hp(1-9) and Hp(1-7) might prefer a receptor conformation or binding site different from those of the non-peptidic cannabinoid agonists. In contrast, the RVD-extended hemopressin (pepcan 12) displayed the lowest binding affinity (K i = 1940 ± 121 nM) to the [ 3 H]Hp(1-7) labeled sites. The findings of the saturation and competition binding studies indicated the existence of a non-cannabinoid binding site or a receptor protein. In order to provide further evidences for this assumption, the ability of cannabinoid ligands and hemopressins to compete with [ 3 H]Hp(1-7) in CB1 knockout mouse brain membrane homogenate was investigated (Fig. 4B.) . It was found that Hp(1-7) displayed the lowest inhibitory constant (K i = 94 ± 25 nM), and this affinity was close to that detected in rat brain membrane homogenate (Table 3. ). The similar affinity values obtained for Hp(1-7) in the homologue displacement studies both in rat and CB1 knockout mouse brain membrane homogenates strongly suggest that the receptor of the Hp(1-7) peptide has to be present in both tissue samples. Furthermore, the higher differences in inhibitory constants (K i = 184 ± 28 nM vs. 401 ± 78 nM) for the Hp(1-9) peptide in rat and CB1 knockout mouse brain homogenates may refer to binding to different regions of the same receptor in the two species or binding to the same region of the receptors with sequence heterogeneity in the two mammalian species. Similarly to the findings in whole rat brain membrane homogenate, the RVD-Hp(1-9) peptide showed marginal binding affinity (K i = 3208 ± 396 nM) to the [ -10 −5 M of Hp(1-7) (•), Hp(1-9) (▲) or RVDHp(1-9) (▼). Non-specific binding was measured in the presence of 10 μM Hp(1-7).
Data are means ± S.E.M., n = 3. highest efficacy (E max = 165 ± 25%) and lowest potency (EC 50 = 9.5 ± 1.2 nM) in good agreement with literature data (Atwood et al., 2010) (Fig. 5.) . Rimonabant also behaved as described in the literature (Zador et al., 2014) . The Hp(1-7) peptide displayed low potency (EC 50 = 21 ± 1.5 nM) and marginal stimulatory activity (E max = 112 ± 8%) as compared to the well-known non-peptidic cannabinoids ( Fig. 5 and Table 4 ). Hp(1-9) also showed low potency (EC 50 = 29 ± 3.5 nM), but did not activate [ 35 S]GTPγS binding (E max = 104 ± 7%). Next, Hp(1-7) and Hp(1-9) were tested in [ 35 S]GTPγS binding assays using membranes prepared from the brain of CB1 knockout mice. We used the opioid full agonist DAMGO as a positive control to compare [ 35 S]GTPγS activation and to test the validity of our experimental model ( Fig. 6 and Table 5 ).
The agonist control compound DAMGO exhibited low potency (EC 50 = 177 ± 21 nM) and significant stimulation (E max = 167 ± 20%) of [
35 S]GTPγS binding as compared to Hp(1-7) and Hp(1-9).
The Hp(1-7) peptide demonstrated a higher potency value (EC 50 = 655 ± 98 nM), in comparison with the potency obtained in rat brain membrane homogenate. However, Hp(1-7) displayed very similar stimulatory effects in both wild type rat brain and CB1 knockout mouse brain homogenates (E max = 112 ± 12 and 117 ± 18%). Similarly to the competitive displacement studies this finding suggests that the ligand activates a G-protein or binds to a protein through the same binding site or receptor protein(s) that is/are present in both types of tissues. Consequently, its main target protein cannot be the CB1 receptor because it is not supposed to be present in the brain membrane preparation of CB1 knockout mice. The Hp(1-9) peptide showed higher potency (EC 50 = 65 ± 12 nM), but a stimulatory effect (E max = 111 ± 17%) roughly equivalent with that of the Hp(1-7) peptide. This difference in the potency value may reflect different binding mode or interaction of the Hp(1-9) peptide with its binding partner.
Discussion
The endocannabinoid system is involved in the regulation of many physiological and pathological processes, therefore, a better understanding of its function is of high importance (Pacher et al., 2006) . The recently discovered α-hemoglobin derived hemopressins have been postulated to be negative allosteric modulators and endogenous agonist ligands of the CB1 receptors. These peptides have been demonstrated to possess in vitro and in vivo pharmacological potencies similar to those of the prototypic endogenous and synthetic cannabinoid ligands, but with less side-effects (Dale et al., 2005; Heimann et al., 2007; Gomes et al., 2009; Bomar and Galande, 2012) . Accordingly, hemopressins have appeared to be excellent lead compounds for the development of peptidic research tools for the investigation of the endocannabinoid system. Their reported pharmacological characteristics have prompted us to prepare a radiolabeled peptide ligand that acts on the CB1 receptor and thus, enables the direct investigation of the endocannabinoid system and the binding properties of new synthetic CB1 receptor ligands.
The Hp(1-9) peptide and its extended or truncated derivatives were demonstrated to be orally active and to exert antinociceptive effects that were apparently mediated by the CB1 receptors (Bomar and Galande, 2012) . The physiological activity upon oral administration suggests that these peptides are at least partially resistant to proteolysis, and also that they may be able to cross the blood-brain barrier. Due to these favorable characteristics and to the fact that the truncated Hp(1-7) peptide was also found to be as potent as Hp(1-9) in in vitro and in vivo studies (Heimann et al., 2007) , Hp(1-7) was chosen for radiolabeling without any structural modification.
The tritium labeled Hp(1-7) was investigated in various radioligand binding assays to characterize the interaction of Hp(1-7) and CB receptors. Data analysis of receptor binding kinetics of [ (1-7) showed that the radioligand reaches equilibrium and steady-state very fast under the experimental conditions. Saturation binding experiments revealed single-site binding and very high receptor densities in both wild type rat brain membrane and CB1 knockout mouse brain membrane homogenates. In displacement studies, the radioligand was not able to compete with the most commonly used CB1 receptor agonist/inverse agonist cannabinoid ligands. However, we found competition with Hp(1-9) in both types of brain homogenates which suggests that both Hp(1-7) and Hp(1-9) may be able to bind to the same receptor binding pocket or allosteric site. This result is contradictory because the CB1 Nonspecific binding was determined by the addition of 10 μM unlabeled GTPγS. Data are means ± S.E.M, n = 3, each performed in triplicate. Hp(1-9) (▼). Non-specific binding was measured in the presence of 10 μM GTPγS. Data are means ± S.E.M., n = 3. Nonspecific binding was determined by the addition of 10 μM unlabeled GTPγS. Data are means ± S.E.M, n = 3, each performed in triplicate.
knockout mouse brain homogenate is not supposed to contain CB1 receptors. Nonetheless, the presence of allosteric binding site on CB1 receptors for hemopressins has been demonstrated (Bauer et al., 2012 , Straiker et al., 2015 . More than 400 different GPCRs have been shown to be encoded in the human genome. Many of them, such as the muscarinic acetylcholine, adenosine, α-adrenergic, bombesin, melatonin, melanocortin, neurotensin, neuromedin, orexin, galanin, opioid, serotonin and tachykinin receptors have been reported to mediate either hypotensive, antinociceptive and/or antihyperalgesic effects through inhibitory or stimulatory pathways (Stone and Molliver, 2009) . Though, the abundance of these mainly neuropeptide receptors is usually much lower than that observed for the CB1 in the brain, these receptors may serve as specific or non-specific binding partners for Hp(1-7), and can be highly expressed in mammalian brains under physiological or pathological conditions. There are many observations supporting the evidence that hemopressins may indirectly regulate the function of other GPCRs and mediate their analgesic, antihyperalgesic and hypotensive effects likely through one or more of these receptor proteins or ion channels. Indeed, a recent exciting study has pointed to the role of TRPV1, a non-selective ligand-gated cation channel that has been proven to promote central anxiogenic effects in animal model of anxiety following i.c.v. administration of Hp(1-9) (Fogaça et al., 2015) . This effect could be blocked by the addition of a TRPV1 antagonist further demonstrating the fact that the observed effects were mediated via a CB1 receptorindependent manner. In our functional (Szlavicz et al., 2015) . It was found that Hp(1-7) and Hp(1-9) slightly activated G-proteins in a naloxone-sensitive manner and that the peptides directly interacted with the CB1 and MOP receptors as well. These results support our hypothesis that hemopressins can directly or indirectly interact with other G-protein coupled receptors in different in vitro model systems and emphasize the importance of the implied experimental model. The brain derived neuropeptide FF (NPFF) and its receptors are well-known modulators of the opioid system. This system was shown to interact with the CB1 receptor as well. NPFF has recently been published to modulate cannabinoid-induced antinociception after i.c.v. administration of mouse VD-hemopressin(α) (an extended analog of Hp(1-9)) in naive and VD-hemopressin(α) tolerant mice (Pan et al., 2015) . In naive mice, i.c.v. injection of NPFF dose-dependently attenuated central analgesia of VD-hemopressin(α). The VD-hemopressin(α)-modulating activities of NPFF and related peptides could be antagonized by NPFF receptor selective antagonists. These results indicate a direct interaction between hemopressins and the NPFF system. Galanin is another GPCR-acting neuropeptide that is widely expressed in the brain and is a common inhibitor of action potential in neurons. Hofer and co-workers have recently found co-localization and production of this neuropeptide with peptide endocannabinoids (pepcans) in specific regions of the rodent CNS (Hofer et al., 2015) . They found enhanced immunostaining and co-localization of RVD-Hp(1-9) (pepcan 12) with galanin in the hippocampus and cerebral cortex, along with the anterograde axonal bundles. However, no immunolabeling could be detected in dopaminergic neurons. These findings further confirm the fact that hemopressins can widely interact with various endogenous neuropeptide systems and can co-regulate pain perception and alleviation.
Based on our direct in vitro receptor binding results and the large number of literature data, we hypothesize that hemopressins indirectly interact with the CB1 receptor. They more likely up-regulate the endocannabinoid production and the subsequent endocannabinoid release may be responsible for the observed analgesic effects. This assumption seems to be further supported by the study of Toniolo and co-workers (Toniolo et al., 2014a (Toniolo et al., , 2014b . They found that hemopressin could inhibit monoacylglycerol-lipase activity in dorsal root ganglions and this might lead to an increase of 2-arachidonoyl-glycerol inducing analgesia. They also hypothesized that hemopressin can interact with the peripheral voltage-gated potassium channels and reduce calcium influx in a synergistic manner with the peripheral cannabinoid receptors. It was also concluded that hemopressin can induce an increase of endocannabinoid level and this would, in turn, lead to the activation of descending inhibitory pain pathways inducing analgesia. However, we cannot fully exclude the existence of allosteric binding site for hemopressins, especially based on the recent findings of Straiker and co-workers (Straiker et al., 2015) . They studied positive and negative allosteric modulators of the endocannabinoid-mediated synaptic transmission in cultured hippocampal neurons. In their study, RVD-Hp(1-9) that did not apparently exhibit binding to the CB1 receptor in our system attenuated depolarization-induced suppression of excitation. Interestingly, Hp(1-9) was ineffective in this model of endocannabinoid signaling. These outcomes shed light on the importance of the implied model system and on variations between the potencies and interaction of endocannabinoids/pepcans with their respective receptors.
Since hemopressins have been reported to possess outstanding pharmacological properties in many in vivo models, further in-depth in vitro and in vivo studies will be necessary for the delineation of Hp(1-7) binding site and its pharmacological significance in mammalian species.
